Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
Completed · Phase 2 · Has a placebo group
Conditions studied: Glabellar Lines
In brief
This is Multicenter, Randomized, Double-blind, Placebo-controlled, Single-dose Study to evaluate Safety and Efficacy of JTM201 in patients with Moderate or Severe Glabellar Lines
Key facts
- Study ID
- NCT06246552
- Run by
- Jetema USA Inc.
- People needed
- 480
- Starts
- 2024-10-26
- Expected to finish
- 2025-06-05
- Last updated by the study team
- 2025-08-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects ≥18 years of age based on the date of the written informed consent form.
- Subject is able to provide written informed consent and comply with study procedures.
- Subject has moderate or severe glabellar lines on maximum frown as assessed by the investigator and subject using the GLS (score of 2 or 3).
You may not qualify if…
- Previous insertion of permanent material in the glabellar area including the forehead.
- Planned treatment with botulinum toxin of any serotype in any other body region during the study period.
- Pregnant or breastfeeding (directly or via pump); or planning to become pregnant during the study.
- Known allergy or hypersensitivity to botulinum toxin or product excipients.
- Participation in another interventional clinical study ≤30 days of Visit 1: Screening.
- Planning to donate, bank, or retrieve eggs (ova, oocytes) or donate sperm during the study.
Where it is running
- Ablon Skin Institute & Research Center — Manhattan Beach, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.